

Vienna, May 18, 2018

Siemens expands digitalization solutions for the process industries

- **Technical prerequisites for Industrie 4.0 fulfilled**
- **Personalized medicine is driving digitalization of the pharmaceutical industry**
- **IoT solutions as a growth driver**

The digital transformation of the industrial sector is in full swing: with its Digital Enterprise portfolio, Siemens has fulfilled the technical prerequisites for implementing *Industrie 4.0*, the Fourth Industrial Revolution. As a result, companies of any size or industry can immediately begin using “digital twins” across the entire value chain in order to increase their competitiveness over the long term. “With our Digital Enterprise portfolio, our customers are now already achieving improvements in flexibility, time-to-market, efficiency and quality,” said Eckard Eberle, CEO of Siemens’ Process Automation Business Unit, at a press event in Vienna, Austria. “With these capabilities, they can successfully tackle some of the challenges that the process industries are currently facing. The growing importance of personalized medicine, for instance, is strengthening demand within the pharmaceutical industry for digital technologies that enable continuous, paperless production in smaller batches all the way down to a lot size of one.”

“Novel and innovative autologous cell therapeutics are now giving us, for the first time, the chance to heal cancer, rather than just treat it. Manufacturing thousands of individual batches in parallel – with each batch based on cell material coming from a single patient and going back to the same patient – requires new solutions for manufacturing, for data management and for all the supply chain logistics. Digital technologies and smart, self-learning automation will be the pioneers that enable broad commercialization of these novel therapies,” said Daniela Buchmayr, Group Director Innovation and Application Development at GEA CEE GmbH.

Analysts at ARC estimate that the market for operations technology software in the process industries will grow by an average of seven percent annually for the next five years. This is particularly the case for the fields of pharmaceuticals and biotechnology, which will see above-average annual growth rates of about nine percent during this period.

For this reason, Siemens is driving the digitalization of the process industries in combination with research and practical applications in the process industries: the Living Lab for Process Industries in Vienna, for instance, enables real-life demonstrations of biotechnological production processes. Key activities include the practically oriented implementation of research topics in the form of projects or case studies, with Siemens customers and employees participating in these activities – for example in the form of training. Among other things, the Living Labs staff is researching the possibilities that the cloud-based, open IoT operating system MindSphere offers for the process industries. In this way, the data generated during the manufacturing process can be stored securely in the cloud, analyzed and used to optimize systems.

Further information on Siemens at Achema 2018 is available here:

www.siemens.com/press and at <https://www.siemens.com/press/achema2018>

Contact for the business press:

Harald Hassenmüller

Tel.: +49 (89) 636-32187; e-mail: harald.hassenmueller@siemens.com

Contact for the trade press:

Dr. David Petry

Tel.: +49 (9131) 7-26616; e-mail: david.petry@siemens.com

Follow us on **social media:**

Twitter: www.twitter.com/MediaServiceInd and www.twitter.com/siemens_press

Blog: <https://blogs.siemens.com/mediaservice-industries-en>

Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for 170 years. The company is active around the globe, focusing on

the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is a leading supplier of efficient power generation and power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. With its publicly listed subsidiary Siemens Healthineers AG, the company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2017, which ended on September 30, 2017, Siemens generated revenue of €83.0 billion and net income of €6.2 billion. At the end of September 2017, the company had around 377,000 employees worldwide. Further information is available on the Internet at www.siemens.com.

This document contains statements related to our future business and financial performance and future events or developments involving Siemens that may constitute forward-looking statements. These statements may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Siemens' management, of which many are beyond Siemens' control. These are subject to a number of risks, uncertainties and factors, including, but not limited to those described in disclosures, in particular in the chapter Risks in the Annual Report. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Siemens may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Siemens neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.